

# 4DMedical webinar - Dr David Shulkin

## 15th January 2024

**Melbourne, Australia, 15**<sup>th</sup> **January 2024**: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") is pleased to invite shareholders, investors and interested parties to attend a webinar on Thursday, 18th January 2024 at 10.00am AEDT.

The webinar will be hosted by David Nayagam, Executive Director Healthcare Research, Evans & Partners, who will interview Dr David Shulkin, Ninth Secretary, U.S. Department of Veterans Affairs and advisor to 4DMedical. Dr Andreas Fouras, Founder and CEO of 4DMedical will also participate in the discussion.

### **Investor Webinar Registration Details**

Please register in advance using the following links:

Phone registration: https://s1.c-conf.com/diamondpass/10036292-zx3shy.html

Webcast: <a href="https://ccmediaframe.com/?id=qsaJBjkv">https://ccmediaframe.com/?id=qsaJBjkv</a>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.

#### -ENDS-

Authorised by the 4DMedical Board of Directors.

#### **Contacts**

Corporate	Administration	Media Enquiries
Chief Financial Officer	Company Secretary	The Capital Network (TCN)
Simon Glover	Naomi Lawrie	Julia Maguire
sglover@4dmedical.com	companysecretary@4dmedical.com	julia@thecapitalnetwork.com.au

#### **About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

4DMedical's reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.



### **About Imbio**

Imbio is a leader in artificial intelligence (AI) medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

For more information, please visit www.imbio.com.